ZURICH (dpa-AFX Broker) - The major Swiss bank UBS has lowered its target price for Schott Pharma from 40 to 33 euros, but left its rating at "Neutral". Analyst Olivier Calvet adjusted his valuation model to the weaker outlook for the polymer syringe business in his review of the profit warning published on Monday./ag/men

Publication of the original study: 19.05.2024 / 19:41 / GMT

First dissemination of the original study: 20.05.2024 / time not specified in study / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------